DSGN — Design Therapeutics, Inc.
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 56
- Website: https://www.designtx.com
Latest SEC filings for DSGN
- 8-K — 2026-06-11
- SCHEDULE 13G — 2026-06-09
- 8-K — 2026-05-18
- 8-K — 2026-04-28
- 10-Q — 2026-04-28
- ARS — 2026-04-23
- 8-K — 2026-04-01
- 3 — 2026-04-01
- S-8 — 2026-03-09
- 8-K — 2026-03-09
Latest DSGN news
- — Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027 (seekingalpha.com)
- — Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program (seekingalpha_market)
Educational tool only — not investment advice.